Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Juno Ends JCAR015 Development In ALL, Cementing Third Place CAR-T Position

Mar 02 2017

• By Mandy Jackson

T-cells attacking cancer_1200x675

Related Content

Kite On Course For FDA Filing On Positive CAR-T Durability Data

Mar 01 2017

Celgene shows CAR-T confidence with $1bn Juno investment

Jun 30 2015

INTERVIEW: Juno CEO Hans Bishop On The CAR-T Learning Curve

Sep 02 2016

ASH Ends With Consistent Kite CAR-T Data, Some Hope For Juno

Dec 07 2016

Three Deaths In Trial Mean Clinical Hold For Juno’s Lead CAR-T Therapy

Jul 07 2016

Juno Stresses Differences Between Its CAR-Ts As JCAR015 Trial Put On Hold Again

Nov 24 2016

IPO Update: Juno has biggest 2014 offering as investors chase CAR-T stocks

Dec 21 2014

Juno-Novartis CAR-T Settlement Puts Focus Back In Clinic

Apr 06 2015

Related Companies

Bristol Myers Squibb Company

Bristol Myers Squibb Company

Kite Pharma, Inc.

Novartis AG

Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center

University of Pennsylvania

St. Jude Children's Research Hospital

Additional Topics

Companies Business Strategies Commercial Cancer BioPharmaceutical

More from Anticancer

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window